International Journal of
Molecular Sciences

MDPI

Article

Acanthopanax senticosus Saponins Mitigate Left Ventricular Remodelling and Inhibit the Induction of MMP-2, MMP-9 in a Rat Model of Myocardial Infarction

Xinjie Li [1], Bingshu Quan [2] and Jianpeng Guo [1,*]

[1] College of Pharmacy, Yanbian University, 977 Gongyuan Road, Yanji 133002, China; 1234182023@ybu.edu.cn
[2] Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, China
* Correspondence: gjp807@ybu.edu.cn

Abstract

Acute myocardial infarction can lead to ventricular remodelling, which affects ventricular function and survival prognosis. Therefore, improving ventricular remodelling has become a focus of research. This study aims to investigate the effect of *Acanthopanax senticosus* leaf saponins (ASS) on cardiac function and left ventricular remodelling in a rat model of myocardial infarction, and explore its potential mechanism. Coronary artery ligation was used to establish a rat model of myocardial infarction, and ASS was administered orally for 28 days. After 28 days, cardiac function was evaluated by hemodynamic detection, and the levels of myocardial enzymes, inflammatory cytokines, oxidative stress and fibrosis-related factors were detected. The degree of fibrosis was evaluated by immunohistochemical detection of collagen I and collagen III deposition. The expression levels of MMP-2, MMP-9 and TIMP-1 were checked by Western blot. Compared with the Sham group, the cardiac function of the Model group was significantly impaired, and ASS administration could improve this change. In addition, compared with the Model group, ASS significantly alleviated myocardial injury, reduced the release of inflammatory cytokines TNF-α and IL-β, improved the oxidative stress state, reduced the release of NT-propBNP, Ang II, ET-1 and inhibited myocardial fibrosis. Moreover, ASS could reduce the expression of MMP-2 and MMP-9, and increase the expression level of TIMP-1. In conclusion, ASS may inhibit left ventricular remodelling by reducing the expression of MMP-2 and MMP-9.

Keywords: *Acanthopanax senticosus* leaf saponins (ASS); ventricular remodelling; myocardial fibrosis; MMP-2; MMP-9

Check for updates

Academic Editor: Michele Correale

Received: 31 January 2026
Revised: 20 February 2026
Accepted: 28 February 2026
Published: 4 March 2026

Copyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

1. Introduction

Data from the Global Burden of Disease 2021 show that ischemic heart disease ranks first among the causes of death worldwide. The high incidence and mortality of end-stage heart failure pose a severe challenge to global public health [1]. Acute myocardial infarction (AMI), as a major cause of heart failure, has significantly improved the survival rate of patients through reperfusion therapy. However, the probability of AMI patients progressing to chronic heart failure within one year is as high as 12% [2,3]. According to statistics, there are 64 million heart failure patients worldwide [4]. Therefore, it is crucial to seek effective diagnosis and treatment methods to delay or even terminate the progression of ventricular remodelling in patients with heart failure before their cardiac function deteriorates significantly [5].

The mechanism of ventricular remodelling is highly complex, encompassing a cascade of pathological changes. Myocardial cells undergo hypertrophy, apoptosis, or necrosis in response to hypoxia and increased load, which in turn alters ventricular wall thickness. Within the extracellular matrix, excessive collagen deposition or an imbalance in collagen degradation impairs the structural integrity and elasticity of the myocardium [6]. Concurrently, overactivation of systems such as the renin–angiotensin–aldosterone system and the sympathetic nervous system further exacerbates myocardial fibrosis, cardiomyocyte apoptosis, and electrophysiological disturbances through the action of hormones and cytokines (e.g., angiotensin II, endothelin-1, and tumor necrosis factor-α) [7–9]. Ultimately, these processes cause the ventricle to transform from its normal elliptical shape to a spherical one, with progressive deterioration of both systolic and diastolic function.

How to reduce or even reverse myocardial fibrosis and ventricular remodelling to improve cardiac function has long been a difficult issue in the treatment of myocardial infarction.

Traditional Chinese Medicine (TCM) is receiving increasing attention due to its unique and significant effects. *Acanthopanax senticosus Harms* (ASH) belongs to the Araliaceae family, Acanthopanax genus, also known as ginseng or lion ginseng, and is a deciduous shrub plant. It is native to Northeast Asia. ASH was mainly distributed in the Korean Peninsula, Japan, northeastern China, and the eastern coast of Russia [10]. It was used in traditional Chinese, Korean, and Japanese medicine for over 2000 years [11,12]. In China, it was called "Ciwujia". ASH contains triterpenoid saponins, flavonoids, carbohydrates, coumarins, essential oils, lignans and polysaccharides, vitamins, amino acids, lipids, and minerals [11]. Saponins are considered the main active components, with the highest concentration in the rhizome. ASH has multiple pharmacological activities, such as anti-inflammatory, anti-cancer, anti-oxidant, anti-bacterial, anti-gout, anti-diabetic, anti-ulcer, anti-hepatitis, and anti-pyretic effects, as well as choleretic, hemostatic, immunostimulatory and cardiovascular and cerebrovascular protective effects [13–17].

Acanthopanax senticosus leaf saponins (ASS) were isolated and extracted with ASH. In this study, the effects of ASS on cardiac dysfunction and ventricular remodelling were evaluated in a rat model of myocardial infarction. Furthermore, the molecular mechanisms through which ASS exerts cardio-protective effects were elucidated.

2. Results

2.1. The Effect of ASS on Hemodynamics in Rats with Ventricular Remodelling

Compared with the Sham group, the SBP, DBP, MAP, LVSP and ±dp/dt max of the Model group were significantly reduced ($p < 0.01$), while LVEDP was significantly increased ($p < 0.001$). Those results indicated that left ventricular systolic and diastolic function were significantly impaired. The hemodynamic changes of ventricular remodelling were observed in rats after 28 days of myocardial infarction. Compared with the Model group, the ASS 50 and 100 mg/kg groups significantly increased ±dp/dtmax and ±dp/dtmax/LVSP ($p < 0.05$), while the ASS 50 and 100 mg/kg dose groups significantly reduced LVEDP ($p < 0.01$). The ASS had no significant effect on SBP, DBP, MAP and HR. The above results suggest that ASS can significantly improve left ventricular systolic and diastolic function in rats with ventricular remodelling after acute myocardial injury (Table 1).

Table 1. The effect of ASS on hemodynamics in rats with ventricular remodelling.

Group	Dose (mg/kg)	SBP (mmHg)	DBP (mmHg)	MAP (mmHg)	LVSP (mmHg)	
Sham	-	124.8 ± 9.36	98.2 ± 6.4	108.6 ± 7.3	134.0 ± 9.3	
Model	-	109.1 ± 11.0 ##	87.3 ± 11.4 ##	92.5 ± 9.4 ###	119.35 ± 6.9 ##	
ASS	50	112.8 ± 11.8	89.2 ± 16.5	98.2 ± 13.8	122.5 ± 7.0	
	100	103.3 ± 8.63	92.2 ± 9.9	91.9 ± 10.4	124.5 ± 7.2	
Group	**Dose (mg/kg)**	**LVEDP (mmHg)**	**+dp/dtmax (mmHg/s)**	**−dp/dtmax (mmHg/s)**	**+dp/dtmax /LVSP**	**−dp/dtmax /LVSP**
Sham	-	5.1 ± 1.7	5320 ± 750	4750 ± 859	38.4 ± 3.5	34.3 ± 4.9
Model	-	15.3 ± 2.9 ###	4200 ± 850 ##	3550 ± 620 ##	33.5 ± 5.4 #	28.2 ± 4.8 ##
ASS	50	11.6 ± 3.6 *	4920 ± 540 *	4270 ± 630 *	39.9 ± 5.4 *	34.7 ± 4.2 **
	100	10.09 ± 3.8 **	4960 ± 630 *	4650 ± 850 **	43.2 ± 5.5 **	38.3 ± 6.1 **

# $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ compared with the Sham group, * $p < 0.05$, ** $p < 0.01$ compared with the Model group. SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, MAP: Mean Arterial Pressure, LVSP: Left Ventricular Systolic Pressure, LVEDP: Left Ventricular End-Diastolic Pressure.

2.2. The Effect of ASS on Ventricular Weight and Volume in Rats with Ventricular Remodelling

Compared with the Sham group, the LVV, LVLA, LVSA, LVAW, LVRW, RVAW, and RVRW of the Model group rats were significantly increased ($p < 0.01$, $p < 0.001$). Those results indicated that left ventricular remodelling occurred after 28 days of myocardial infarction. Compared with the Model group, the ASS 50 and 100 mg/kg groups significantly reduced LVV, LVLA, LVSA, LVAW, LVRW, RVAW, and RVRW ($p < 0.05$ or $p < 0.01$), but had no significant effect on BW. The above results suggest that ASS can significantly inhibit left ventricular remodelling in rats with acute myocardial infarction (Table 2).

Table 2. The effect of ASS on ventricular weight and volume in rats with ventricular remodelling.

Group	Dose (mg/kg)	BW (g)	LVV (mL)	LVLA (mm)	LVSA (mm)
Sham	-	270.5 ± 22.9	0.38 ± 0.08	12.42 ± 0.19	6.93 ± 1.13
Model	-	261.1 ± 23.2	0.77 ± 0.10 ###	14.29 ± 1.00 ###	10.36 ± 0.83 ###
ASS	50	269.3 ± 18.6	0.62 ± 0.14 *	13.39 ± 0.61 *	9.40 ± 0.70 *
	100	263.6 ± 20.5	0.53 ± 0.13 ***	12.97 ± 0.89 *	9.06 ± 0.79 **
Group	**Dose (mg/kg)**	**LVAW (mg)**	**RVAW (mg/g)**	**LVRW (mg/g)**	**RVRW (mg/g)**
Sham	-	548.2 ± 101.7	138.5 ± 36.2	2.03 ± 0.25	0.51 ± 0.11
Model	-	742.4 ± 123.4 ##	215.6 ± 68.0 ##	2.84 ± 0.57 ###	0.82 ± 0.27 ##
ASS	50	610.7 ± 108.4 *	193.1 ± 64.2	2.24 ± 0.35 *	0.67 ± 0.18

$p < 0.01$, ### $p < 0.001$ compared with the Sham group, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared with the Model group. BW: Body Weight, LVV: Left Ventricular Volume, LVLA: Left Ventricular Long Axis, LVSA: Left Ventricular Short Axis, LVAW: Left Ventricular Absolute Weight, RVAW: Right Ventricular Absolute Weight, LVRW: Left Ventricular Relative Weight, RVRW: Right Ventricular Relative Weight.

2.3. The Effect of ASS on Morphological Changes in Rats with Ventricular Remodelling

The myocardial cells in the Sham group were relatively intact, with neatly arranged muscle fibers and no infarction lesions observed. The Model group showed a thinning of the ventricular wall in the infarct area, dissolution and disappearance of most myocardial fibers after necrosis, fibrous tissue proliferation forming scar tissue, and infiltration of inflammatory cells. The ASS group showed a mild degree of myocardial cell degeneration (Figure 1).




Figure 1. The effect of ASS on morphological changes in rats with ventricular remodelling. magnification = 200×. (**A**) Representative pathological changes. (**B**) Quantitative analyses for Collagen I. (**C**) Quantitative analyses for Collagen III. Data are expressed as mean ± S.D for each group. ## $p < 0.01$ vs. Sham group; ** $p < 0.01$ vs. Model group.

2.4. The Effect of ASS on Myocardial Enzymes in Rats with Ventricular Remodelling

Compared with the Sham operation group, the content of cTnI and the activities of LDH, AST in the Model group increased significantly ($p < 0.01$). Compared with the Model group, the ASS 100 mg/kg groups significantly reduced the content of cTnI and the activities of LDH and AST ($p < 0.01$) (Figure 2).




Figure 2. The effect of ASS on myocardial enzymes in rats with ventricular remodelling. (**A**) The contents of LDH. (**B**) The contents of AST. (**C**) The contents of cTnI. Data are expressed as mean ± S.D for each group. ### $p < 0.001$ vs. Sham group; * $p < 0.05$, *** $p < 0.001$ vs. Model group.

2.5. The Effect of ASS on Oxidative Stress in Rats with Ventricular Remodelling

Compared with the Sham group, the content of MDA in the Model group increased significantly ($p < 0.01$), while the activities of SOD, CAT, and GSH-Px decreased significantly ($p < 0.05$, $p < 0.01$). These results indicate that oxidative stress occurred after 28 days of myocardial infarction. Compared with the Model group, both ASS 50 and 100 mg/kg groups significantly reduced MDA content ($p < 0.05$, $p < 0.01$) and increased serum SOD, CAT, and GSH Px activities ($p < 0.05$, $p < 0.01$) (Figure 3). The above results suggested that ASS can inhibit oxidative stress in rats with acute myocardial infarction.




Figure 3. The effect of ASS on oxidative stress in rats with ventricular remodelling. (**A**) The contents of MDA. (**B**) The activities of SOD. (**C**) The activities of CAT. (**D**) The activities of GSH-PX. Data are expressed as mean ± S.D for each group. # $p < 0.05$, ### $p < 0.001$ vs. Sham group; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. Model group.

2.6. The Effects of ASS on Inflammatory Parameters in Rats with Ventricular Remodelling

Compared with the Sham operation group, the content of TNF-α and IL-1β in the Model group increased significantly ($p < 0.01$). Compared with the Model group, both ASS 50 and 100 mg/kg groups significantly reduced the content of TNF-α and IL-1β in the Model group increased significantly ($p < 0.01$) (Figure 4).




Figure 4. The effects of ASS on inflammatory parameters in rats with ventricular remodelling. (**A**) The contents of TNF-α. (**B**) The contents of IL-1β. Data are expressed as mean ± S.D for each group. ### $p < 0.001$ vs. Sham group; * $p < 0.05$, *** $p < 0.001$ vs. Model group.

2.7. The Effects of ASS on Myocardial Fibrosis in Rats with Ventricular Remodelling

2.7.1. The Effects of ASS on the Contents of NT-proBNP, ET-1, and Ang II

Compared with the Sham group, the contents of NT-proBNP, ET-1, and Ang II of the Model group rats were significantly increased ($p < 0.01$). Those results indicated that left ventricular remodelling occurred after 28 days of myocardial infarction. Compared with the Model group, the ASS 100 mg/kg groups significantly reduced contents of NT-proBNP, ET-1, and Ang II ($p < 0.01$). The above results suggest that ASS can inhibit myocardial fibrosis, reducing the secretion of NT-proBNP, ET-1, and Ang II (Figure 5).




Figure 5. The effects of ASS on the contents of NT-proBNP, ET-1 and Ang II in rats with ventricular remodelling. (**A**) The contents of NT-proBNP. (**B**) The contents ET-1. (**C**) The contents Ang II. Data are expressed as mean ± S.D for each group. ### $p < 0.001$ vs. Sham group; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. Model group.

2.7.2. The Effects of ASS on Myocardial Collagen Deposition

The immunohistochemical staining results showed that compared with the Sham group, some myocardial cells in the Model group were replaced by connective tissue, with obvious fibrosis and increased collagen I/III deposition. Compared with the Model group, the ASS group showed a reduction in connective tissue, decreased distribution of collagen fibers, and reduced degree of myocardial fibrosis (Figure 1).

2.7.3. The Effects of ASS on MMP-2, MMP-9 and TIMP-1

Compared with the Sham group, the protein levels of MMP-2 and MMP-9 in the Model group were significantly increased ($p < 0.05$ or $p < 0.01$), whereas TIMP-1 was significantly decreased ($p < 0.05$ or $p < 0.01$). Compared with the Model group, the ASS 50 and 100 mg/kg groups significantly reduced the protein levels of MMP-2 and MMP-9 and increased TIMP-1 ($p < 0.05$ or $p < 0.01$). These results implied that ASS can inhibit myocardial fibrosis by inhibiting the induction of MMP-2 and MMP-9 (Figure 6).




Figure 6. The effects of ASS on the expression of MMP-2, MMP-9, and TIMP-1 in rats with ventricular remodelling. (**A**) Representative Western blots. (**B**) Quantitative analyses for MMP-2. (**C**) Quantitative analyses for MMP-9. (**D**) Quantitative analyses for TIMP-1. Data are expressed as mean ± S.D for each group. ## $p < 0.01$ vs. Sham group; ** $p < 0.01$ vs. Model group.

3. Discussion

Ventricular remodelling is a pathophysiological process following myocardial infarction, mainly characterized by the progressive enlargement of the left ventricle and its transformation into a spherical shape. This process leads to a decline in cardiac function and eventually progresses to heart failure [18]. In this study, left ventricular cannulation was used to detect hemodynamic parameters. The results showed that the LVP, LVSP, +dp/dtmax, and −dp/dtmin in rats of the Model group were significantly decreased, while LVEDP was significantly increased. These findings suggest that cardiac function gradually deteriorated, progressed to an irreversible stage, and eventually led to death. After intervention with ASS, the changes in the aforementioned parameters were significantly reversed, cardiac function was notably improved, and the trend and degree of deterioration were inhibited.

During the process of myocardial infarction, myocardial cells are subjected to ischemia and hypoxia, which disrupts the intracellular redox balance and promotes an increase in the production of reactive oxygen species (ROS). ROS with high reactivity undergo oxidative reactions with various biomolecules in the cell, thereby causing lipid peroxidation of the cell membrane, DNA strand breaks, and oxidative damage to proteins. These changes further impair the cells and eventually lead to cell death [19]. MDA is a type of peroxide produced when oxygen-free radicals attack unsaturated fatty acids in cell membranes. An increase in MDA indicates the occurrence of lipid peroxidation in the body and severe cell damage, and it is one of the important indicators reflecting the degree of oxidative stress-induced damage in the organism [20]. In our results, ASS increased the activities of SOD, CAT and GSH-Px, and decreased the MDA content. These findings demonstrated that ASS had a protective effect on myocardial damage induced by oxidative stress in rats with ventricular remodelling.

The inflammatory response plays a "double-edged sword" role in ventricular remodelling after acute myocardial infarction [21]. In the early stage, the continuous fluctuation of inflammatory cells and mediators tends to clear necrotic tissue and initiate adaptive myocardial repair. However, a persistent hyperinflammatory state can directly induce cardiomyocyte apoptosis and hypertrophy through proinflammatory factors (e.g., TNF-α, IL-1β). These proinflammatory factors can also upregulate the sensitivity of AT1 receptors in the non-infarcted area, thereby indirectly promoting myocardial fibrosis and triggering an uncontrolled pro-remodelling process [22,23]. In this study, ASS significantly reduced the serum levels of TNF-α and IL-1β in rats and decreased myocardial inflammatory infiltration, suggesting that it exerts a significant anti-inflammatory effect.

Levels of Ang II, ET-1, and BNP are associated with ventricular remodelling. Ang II can exacerbate cardiac fibrosis and induce ventricular remodelling, accompanied by oxidative stress responses and inflammatory reactions [24]. ET-1 is the most important vasoconstrictor in the cardiovascular system; it is involved in the occurrence and development of endothelial dysfunction and inflammation, as well as the process of vascular remodelling. Increased ET-1 levels in myocardial tissue can lead to myocardial fibrosis and ventricular systolic and diastolic dysfunction, and endothelin antagonists can improve myocardial fibrosis and ventricular remodelling [25,26]. Studies have shown that the rate of decrease in BNP levels over 3 consecutive months is an important independent predictor of left ventricular remodelling [27]. In this study, it was found that after intervention with ASS, the serum levels of Ang II, ET-1, and BNP in rats were all reduced, suggesting that ASS exerts an inhibitory effect on ventricular remodelling after acute myocardial infarction.

Matrix metalloproteinases (MMPs) are key enzymes that regulate extracellular matrix (ECM) metabolism, and their abnormal activity is closely related to ventricular remodelling. The core of ventricular remodelling is the imbalance between ECM synthesis and degradation. When MMPs are overactivated, they will degrade a large amount of ECM components such as collagen and elastin, damaging the structural integrity of myocardial tissue, leading to myocardial fibrosis disorder, disordered arrangement of myocardial cells, and ultimately inducing ventricular hypertrophy and chamber enlargement [28]. Meanwhile, MMPs can exacerbate the decline in myocardial mechanical stability, promote remodelling progress, and gradually impair cardiac function [29]. The activity of MMPs is regulated by tissue inhibitory factors, and the imbalance between the two is an important pathological link in the occurrence and development of ventricular remodelling, which also provides potential targets for interventions in related cardiovascular diseases.

4. Materials and Methods

4.1. Animals

A total of 50 male Wistar rats were provided by the Experimental Animal Center of Yanbian University. All animals were maintained in a 12 h light, 12 h dark cycle room with the temperature at 22–24 °C. All rats had free access to a standard diet and drinking water. The animal experiment was approved by the Animal Management and Use Committee of Yanbian University (YD202509130055).

4.2. Reagent

Acanthopanax senticosus saponins (ASS) (purity > 88%) were purchased from LMAI Bio, (Shanghai, China). ELISA kits for Cardiac Troponin I (cTnI), TNF-α, IL-β, and NT-proBNP were purchased from Nanjing Jiancheng Biotechnology (Nanjing, China). The kits of Malondialdehyde (MDA), Superoxide Dismutase (SOD), Lactate Dehydrogenase (LDH), and Glutathione Peroxidase (GSH-Px) assay kits were purchased from Nanjing Jiancheng Biotechnology (Nanjing, China). ELISA kits for Angiotensin II (Ang II) and Endothelin-1 (ET-1) were purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd. (Shanghai, China). Antibodies against MMP-2, MMP-9, and Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) were purchased from Abcam (Cambridge, MA, USA). Antibody against β-actin was obtained from Beijing Dingduo Changsheng Biotechnology (Beijing, China).

4.3. Establishment of Left Ventricular Remodelling Model

The left ventricular remodelling model was established as previously described [30]. The acute myocardial infarction Model was established by ligation of the left anterior descending (LAD) coronary artery, as described previously. Briefly, rats were anaesthetized with 2% pentobarbital sodium solution (10 mL/kg). These rats underwent endotracheal intubation and were connected to a ventilator. Open the chest, expose the heart, and ligate the anterior descending (LAD) coronary artery with 6-0 Prolene suture. The heart was sent back to the chest, and the thorax was closed. The sham group underwent the same surgical procedure without LAD ligation. Penicillin was injected for one week to prevent infection.

4.4. Animals Treatment

24 h after operation, thirty-six surviving rats underwent electrocardiogram examination, and about 90% of the model rats showed ST segment elevation, which was randomly divided into three groups (with 12 rats in each group): Model group, ASS low dose group (50 mg/kg), and ASS high dose group (100 mg/kg). Those rats were intragastrically administered with ASS once a day for 28 consecutive days. Additionally, 12 rats were randomly

selected as the Sham group. Those rats in the Sham group were administered the same amount of normal saline.

4.5. Measurement of Hemodynamic Parameters

After 28 days of administration, rats were anesthetized by 2% pentobarbital sodium solution (ip). The right common carotid artery was separated, and a plastic tube with an inner diameter was inserted into the left ventricle and connected to the BL-420 Information Integrated Signal Acquisition and Processing System. The left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), and maximum rate of increase and decrease in left ventricular pressure (±dp/dtmax) were measured. At the same time, the femoral artery was separated, and the arterial systolic pressure (SBP) and diastolic pressure (DBP) were measured by intubation. The mean arterial pressure (MAP) was calculated, and heart rate (HR) was synchronously recorded.

4.6. Biochemical Analysis in Serum

After 28 days of administration, rats were anesthetized by 2% pentobarbital sodium solution (ip). Blood was collected from the abdominal aorta. The activities of LDH, AST, SOD, CAT, GSH-Px, and the content of cTnI, MDA, TNF-α, IL-1 β, NT-proBNP, Ang II and ET-1 were measured according to the manufacturer's instructions.

4.7. Morphology Determination

After 28 days of administration, rats were anesthetized by 2% pentobarbital sodium solution (ip). The hearts were dissected and placed in 10% neutral formalin for 72 h. Myocardial tissues were prepared using conventional HE staining, and pathological changes in the myocardial tissue were observed and photographed under an optical microscope.

4.8. Immunohistochemical Staining

Myocardial tissues were deparaffinized, rehydrated with ethylenediaminetetraacetic acid antigen, and sealed. Incubated with collagen I (1:300) and collagen III (1:300) primary antibodies overnight at 4 °C. Stained with 3,3′-diaminobenzidine and determined the positive expression level based on the degree and range of brown staining.

4.9. Western Blotting

The protein of the myocardial tissues was detected by the BCA assay. The protein was separated by SDS -PAGE gel electrophoresis and was transferred to the PVDF membrane. The membrane was sealed with 5% BSA and was incubated with MMP-2 and MMP-9 overnight at 4 °C. After incubation with a secondary antibody, the protein bands were visualized by ECL. ImageJ software, version 1.8.0 was used to perform grayscale analysis. β-actin was used as the internal reference protein.

4.10. Statistical Analysis

The experimental data were processed using SPSS 10.0 statistical software. The results are presented in the form of mean ± standard deviation. The intergroup differences are compared using Tukey's one-way ANOVA and Student's *t*-test. The Shapiro–Wilk test was used to check the normal distribution of continuous variables. $p < 0.05$ indicates a statistically significant difference.

5. Conclusions

In conclusion, ASS can exert an inhibitory effect on ventricular remodelling through multiple pathways. Its mechanisms of action include improving cardiac hemodynamic function, mitigating myocardial tissue injury, modulating oxidative stress levels, reducing the expression of myocardial fibrosis-related factors to suppress excessive collagen deposition, and concurrently regulating the MMP-2/MMP-9 signaling pathway to maintain the balance of myocardial matrix metabolism.

Author Contributions: Conceptualization: J.G.; methodology, investigation, and model establishment: X.L.; writing—original draft: X.L. and B.Q.; writing—reviewing and editing: J.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The animal experiment was approved by the Animal Management and Use Committee of Yanbian University (Approval Code: YD202509130055; Approval date: 13 September 2025).

Informed Consent Statement: Not applicable.

Data Availability Statement: The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

SOD	Superoxide Dismutase
MDA	Malondialdehyde
CAT	Catalase
GSH-PX	Glutathione peroxidase
IL-1β	Interleukin-1β
LDH	Lactate dehydrogenase
AST	Aspartate aminotransferase
Ang II	Angiotensin II
ET-1	Endothelin-1

References

1. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. *Lancet* **2024**, *403*, 2100–2132, Correction in *Lancet* **2024**, *403*, 1988. [CrossRef] [PubMed]
2. Bozkurt, B.; Ahmad, T.; Alexander, K.M.; Baker, W.L.; Bosak, K.; Breathett, K.; Fonarow, G.C.; Heidenreich, P.; Ho, J.E.; Hsich, E.; et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. *J. Card. Fail.* **2023**, *29*, 1412–1451. [CrossRef]
3. Harrington, J.; Butler, J. Heart failure after myocardial infarction: Glass emptier than full. *Eur. J. Heart Fail.* **2023**, *25*, 1225–1227. [CrossRef]
4. Savarese, G.; Becher, P.M.; Lund, L.H.; Seferovic, P.; Rosano, G.M.C.; Coats, A.J.S. Global burden of heart failure: A comprehensive and updated review of epidemiology. *Cardiovasc. Res.* **2023**, *118*, 3272–3287, Correction in *Cardiovasc. Res.* **2023**, *119*, 1453. [CrossRef]
5. Aune, D.; Schlesinger, S.; Leitzmann, M.F.; Tonstad, S.; Norat, T.; Riboli, E.; Vatten, L.J. Physical activity and the risk of heart failure: A systematic review and dose-response meta-analysis of prospective studies. *Eur. J. Epidemiol.* **2021**, *36*, 367–381. [CrossRef]
6. Zhu, E.; Yuan, C.; Hu, S.; Liao, Y.; Li, B.; Zhou, Y.; Zhou, W. Injection of Matrix Metalloproteinase-9 Leads to Ventricular Remodeling. *Dis. Markers* **2022**, *2022*, 1659771. [CrossRef]

7. Qu, Y.; Ma, D.; Wu, T.; Wang, H.; Tian, Z.; Liu, X.; Wang, Y. A multi-omics approach identifies the key role of disorders of sphingolipid metabolism in Ang II-induced hypertensive cardiomyopathy myocardial remodeling. *Sci. Rep.* **2024**, *14*, 30379. [CrossRef]
8. Wang, L.; Lin, S.; Wei, Q.; Li, T.; Mo, Q.; Bai, R.; Feng, J.; Zhan, A.; Yang, X.; Rong, X.; et al. Preventive Administration of Quercetin Promotes Survival and Reduces Adverse Ventricular Remodeling after myocardial infarction through facilitating M2-like macrophage polarization. *Int. Immunopharmacol.* **2025**, *151*, 114296. [CrossRef]
9. Luo, Q.; Liu, Q.; Tang, K.; Zhong, B.; Yang, S.; Li, X. Phillyrin improves myocardial remodeling in salt-sensitive hypertensive mice by reducing endothelin1 signaling. *J. Pharm. Pharmacol.* **2024**, *76*, 672–680. [CrossRef] [PubMed]
10. Jia, A.; Zhang, Y.; Gao, H.; Zhang, Z.; Zhang, Y.; Wang, Z.; Zhang, J.; Deng, B.; Qiu, Z.; Fu, C. A review of *Acanthopanax senticosus* (Rupr and Maxim.) harms: From ethnopharmacological use to modern application. *J. Ethnopharmacol.* **2021**, *268*, 113586. [CrossRef] [PubMed]
11. Kos, G.; Czarnek, K.; Sadok, I.; Krzyszczak-Turczyn, A.; Kubica, P.; Fila, K.; Emre, G.; Tatarczak-Michalewska, M.; Latalska, M.; Blicharska, E.; et al. *Eleutherococcus senticosus* (*Acanthopanax senticosus*): An Important Adaptogenic Plant. *Molecules* **2025**, *30*, 2512. [CrossRef] [PubMed]
12. Li, T.; Ferns, K.; Yan, Z.Q.; Yin, S.Y.; Kou, J.J.; Li, D.; Zeng, Z.; Yin, L.; Wang, X.; Bao, H.X.; et al. *Acanthopanax senticosus*: Photochemistry and Anticancer Potential. *Am. J. Chin. Med.* **2016**, *44*, 1543–1558. [CrossRef] [PubMed]
13. Li, X.T.; Zhou, J.C.; Zhou, Y.; Ren, Y.S.; Huang, Y.H.; Wang, S.M.; Tan, L.; Yang, Z.Y.; Ge, Y.W. Pharmacological effects of *Eleutherococcus senticosus* on the neurological disorders. *Phytother. Res.* **2022**, *36*, 3490–3504. [CrossRef] [PubMed]
14. Huang, Y.H.; Ding, W.L.; Li, X.T.; Cai, M.T.; Li, H.L.; Yang, Z.Y.; Piao, X.H.; Zhu, S.; Tohda, C.; Komatsu, K.; et al. Memory enhancement effect of saponins from *Eleutherococcus senticosus* leaves and blood-brain barrier-permeated saponins profiling using a pseudotargeted monitoring strategy. *Food Funct.* **2022**, *13*, 3603–3620. [CrossRef]
15. Yang, R.; Meng, X.; Zhao, W.; Xu, S.Q.; Wang, S.Y.; Li, M.M.; Guan, W.; Chen, Q.S.; Zhang, L.L.; Kuang, H.X.; et al. Phenylpropanoids of *Eleutherococcus senticosus* (Rupr. & maxim.) maxim. Alleviate oxidative stress in Alzheimer's disease in vitro and in vivo models by regulating Mst1 and affecting the Nrf2/Sirt3 pathway. *Bioorganic Chem.* **2025**, *159*, 108347. [CrossRef]
16. Su, J.; Zhang, X.; Kan, Q.; Chu, X. Antioxidant Activity of *Acanthopanax senticosus* Flavonoids in H(2)O(2)-Induced RAW 264.7 Cells and DSS-Induced Colitis in Mice. *Molecules* **2022**, *27*, 2872. [CrossRef]
17. Wang, Y.; Wang, L.; Zhang, H.; Ren, P.; Cheng, X.; Hong, F.; Liu, J.; Zhang, R.; Zhao, J.; Gou, D. Immunostimulatory effects mechanism of polysaccharide extracted from *Acanthopanax senticosus* on RAW 264.7 cells through activating the TLR/MAPK/NF-kappaB signaling pathway. *Sci. Rep.* **2025**, *15*, 13440. [CrossRef]
18. Jacquin, L.; Battault, M.; Mewton, N.; Mantout, A.; Bergerot, C.; Tazarourte, K.; Douplat, M. Outcome of patients admitted with oxygen mismatch and myocardial injury or infarction in emergency departments. *J. Cardiovasc. Med.* **2023**, *24*, 159–166. [CrossRef] [PubMed]
19. Sies, H.; Belousov, V.V.; Chandel, N.S.; Davies, M.J.; Jones, D.P.; Mann, G.E.; Murphy, M.P.; Yamamoto, M.; Winterbourn, C. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. *Nat. Rev. Mol. Cell Biol.* **2022**, *23*, 499–515. [CrossRef]
20. Alruhaimi, R.S.; Hassanein, E.H.M.; Bin-Jumah, M.N.; Mahmoud, A.M. Cadmium cardiotoxicity is associated with oxidative stress and upregulated TLR-4/NF-kB pathway in rats; protective role of agomelatine. *Food Chem. Toxicol.* **2023**, *180*, 114055. [CrossRef]
21. Frangogiannis, N.G. Regulation of the inflammatory response in cardiac repair. *Circ. Res.* **2012**, *110*, 159–173. [CrossRef] [PubMed]
22. Kologrivova, I.; Shtatolkina, M.; Suslova, T.; Ryabov, V. Cells of the Immune System in Cardiac Remodeling: Main Players in Resolution of Inflammation and Repair After Myocardial Infarction. *Front. Immunol.* **2021**, *12*, 664457. [CrossRef] [PubMed]
23. Peet, C.; Ivetic, A.; Bromage, D.I.; Shah, A.M. Cardiac monocytes and macrophages after myocardial infarction. *Cardiovasc. Res.* **2020**, *116*, 1101–1112. [CrossRef]
24. Chen, H.J.; Pan, X.X.; Ding, L.L.; Ruan, C.C.; Gao, P.J. Cardiac Fibroblast-Specific Knockout of PGC-1alpha Accelerates AngII-Induced Cardiac Remodeling. *Front. Cardiovasc. Med.* **2021**, *8*, 664626. [CrossRef]
25. Gurzau, D.; Sitar-Taut, A.; Caloian, B.; Gusetu, G.; Comsa, H.; Fringu, F.; Zdrenghea, D.; Pop, D. The Role of IL-6 and ET-1 in the Diagnosis of Coronary MicroVascular Disease in Women. *J. Pers. Med.* **2021**, *11*, 965. [CrossRef]
26. Wang, B.; Zhou, R.; Wang, Y.; Liu, X.; Shou, X.; Yang, Y.; Yang, C.; Tong, Q.; Mao, G.; Wu, Q. Effect of high-intensity interval training on cardiac structure and function in rats with acute myocardial infarct. *Biomed. Pharmacother.* **2020**, *131*, 110690. [CrossRef]
27. Hsu, J.T.; Chung, C.M.; Chu, C.M.; Lin, Y.S.; Pan, K.L.; Chang, J.J.; Wang, P.C.; Chang, S.T.; Yang, T.Y.; Jang, S.J.; et al. Predictors of Left Ventricle Remodeling: Combined Plasma B-type Natriuretic Peptide Decreasing Ratio and Peak Creatine Kinase-MB. *Int. J. Med. Sci.* **2017**, *14*, 75–85. [CrossRef]
28. Xing, Y.; Xie, S.; Shi, W.; Zeng, X.; Deng, W.; Tang, Q. Targeting interleukin-21 inhibits stress overload-induced cardiac remodelling via the TIMP4/MMP9 signalling pathway. *Eur. J. Pharmacol.* **2023**, *940*, 175482. [CrossRef] [PubMed]

29. Stassen, J.; Khidir, M.; Galloo, X.; Hirasawa, K.; Knuuti, J.; Marsan, N.A.; Delgado, V.; van der Bijl, P.; Bax, J.J. Prognostic implications of staging cardiac remodeling in patients undergoing cardiac resynchronization therapy. *Int. J. Cardiol.* **2022**, *355*, 65–71. [CrossRef]
30. MacAskill, M.G.; Reid, V.J.M.; Alcaide-Corral, C.J.; Morgan, T.E.F.; Waddell, L.; Thomson, A.J.W.; Fujisawa, T.; Mills, N.L.; Marti, J.A.; Kurian, D.; et al. Longitudinal [^{18}F]LW223 PET imaging of macrophage-driven inflammation following myocardial infarction in a rat model: Implications for left ventricular remodelling. *Eur. J. Nucl. Med. Mol. Imaging* **2025**. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.